CAS 1353020-85-5

2-Hydroxypropyl Nortadalafil (Mixture of Diastereomers)

CAS: 1353020-85-5

Formel: C₂₄H₂₃N₃O₅

Farbe und Form: White To Off-White Solid

Molekulargewicht: 433.46

Ref: 4Z-T-1029

Nortadalafil-N-(2-hydroxy)propyl

CAS: 1353020-85-5

Formel: C₂₄H₂₃N₃O₅

Farbe und Form: Neat

Molekulargewicht: 433.46

Ref: 04-C15651925

2-Hydroxypropyl Nortadalafil (Mixture of Diastereomers)

Kontrolliertes Produkt

CAS: 1353020-85-5

Applications 2-Hydroxypropyl Nortadalafil is a derivative of Tadalafil (T004500), which is used for the treatment of erectile dysfunction. A phosphodiesterase 5 inhibitor.
References Carrier, S., et al.: Can. J. Urol., 10(1), 12 (2003), Doggrell, S.A., et al.: Expert Opin. Pharmacother., 6, 75 (2005), Forgue, S.T., et al.: Br. J. Clin. Pharmacol., 61, 280 (2005), Toomey, V. et al.: J. Pharm. Biomed. Anal., 59, 50 (2012);

Formel: C₂₄H₂₃N₃O₅

Farbe und Form: Neat

Molekulargewicht: 433.46

Ref: TR-H952705

2-Hydroxypropyl-d6 Nortadalafil

Kontrolliertes Produkt

CAS: 1353020-85-5

Formel: C₂₄D₆H₁₇N₃O₅

Farbe und Form: Neat

Molekulargewicht: 439.493

Ref: TR-H952707

Nortadalafil-N-(2-hydroxy)propyl

CAS: 1353020-85-5

Nortadalafil-N-(2-hydroxy)propyl is a chemotherapeutic agent, which is synthesized through the chemical modification of tadalafil. It is characterized as a small-molecule inhibitor, derived from the structural alteration of the well-known phosphodiesterase type 5 (PDE5) inhibitor. The mechanism of action involves the attenuation of PDE5 activity, leading to increased levels of cyclic guanosine monophosphate (cGMP) within targeted cellular pathways. This elevation in cGMP concentration results in vasodilation and increased blood flow, primarily investigated within the context of vascular and erectile tissue.

Formel: C₂₄H₂₃N₃O₅

Reinheit: Min. 95%

Molekulargewicht: 433.5 g/mol

Ref: 3D-DEC02085

2-Hydroxypropyl Nortadalafil (Mixture of Diastereomers)

CAS: 1353020-85-5

Formel: C₂₄H₂₃N₃O₅

Molekulargewicht: 433.46

Ref: ST-EA-CP-T31092